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Viral vaccine vectors have emerged as an attractive strategy for the development of a human immunodefi-
ciency virus (HIV) vaccine. Recombinant Newcastle disease virus (rNDV) stands out as a vaccine vector since
it has a proven safety profile in humans, it is a potent inducer of both alpha interferon (IFN-) and IFN-)
production, and it is a potent inducer of dendritic cell (DC) maturation. Our group has previously generated
an rNDV vector expressing a codon-optimized HIV Gag protein and demonstrated its ability to induce a
Gag-specific CD8 T cell response in mice. In this report we demonstrate that the Gag-specific immune
response can be further enhanced by the targeting of the rNDV-encoded HIV Gag antigen to DCs. Targeting
of the HIV Gag antigen was achieved by the addition of a single-chain Fv (scFv) antibody specific for the
DC-restricted antigen uptake receptor DEC205 such that the DEC205 scFv-Gag molecule was encoded for
expression as a fusion protein. The vaccination of mice with rNDV coding for the DC-targeted Gag antigen
induced an enhanced Gag-specific CD8 T cell response and enhanced numbers of CD4 T cells and CD8 T
cells in the spleen relative to vaccination with rNDV coding for a nontargeted Gag antigen. Importantly, mice
vaccinated with the DEC205-targeted vaccine were better protected from challenge with a recombinant vaccinia
virus expressing the HIV Gag protein. Here we demonstrate that the targeting of the HIV Gag antigen to DCs
via the DEC205 receptor enhances the ability of an rNDV vector to induce a potent antigen-specific immune
response.
Almost 3 decades since the identification of HIV as the
causative agent of AIDS, the development of a prophylactic
vaccine against the virus is still proving to be a daunting task.
Two phase III HIV-1 vaccine trials, Merck’s STEP trial and
VaxGen’s AIDSVAX B/E vaccine trial, failed to prevent
HIV-1 infection and had no effect on viral load in trial partic-
ipants who later became infected (2, 28). A phase III clinical
trial employing Aventis Pasteur’s canarypox virus vector, Al-
vac-HIV (vCP1521), as a prime and VaxGen’s rgp120 (recom-
binant glycoprotein 120) (AIDSVax B/E) as a protein boost
showed a modest reduction in HIV-1 infection (30). The com-
bination of both of these immunogens was intended to elicit
strong HIV-specific humoral and cellular immune responses; it
is widely believed that an effective HIV vaccine will have to
activate both the humoral and cellular arms of the adaptive
immune system (2). Although the underpinnings of the ob-
served degree of protection remain undetermined, this study
emphasized the importance of viral vaccine vectors like the
Alvac-HIV canarypox virus vector as a major component of
any HIV vaccine regimen, since a phase III trial of VaxGen
bivalent rgp120 alone showed no effect on HIV-1 acquisition
(28). The Alvac-HIV canarypox virus vector was shown previ-
ously to induce a low level of HIV-specific CD8 T cells in a
phase II clinical trial (32). The optimization of viral vectors to
enhance the induction of HIV-specific mucosal and systemic
immunity will likely further increase the efficacy of virus-based
HIV vaccine constructs.
Newcastle disease virus (NDV) is a member of the genus
Avulavirus of the family Paramyxoviridae, a genus that does not
include any known natural pathogens of humans. The NDV
genome consists of a small, single-stranded, negative-sense
RNA genome containing six transcriptional units, NP, P, M, F,
HN, and L (1). Several characteristics make NDV a promising
live vaccine vector candidate. First, NDV is well tolerated by
humans. Previously reported clinical trials that employed NDV
for its oncolytic activity demonstrated that repeated intrave-
nous dosing is associated with few adverse side effects (11).
Second, in contrast to viral vectors used in the design of HIV
vaccines, such as adenoviruses (Ad5) or human paramyxovi-
ruses (measles virus and mumps virus), there is no preexisting
immunity to NDV in the majority of the adult human popula-
tion (1). Preexisting antibodies in the host can reduce the
efficacy of a viral vector by diminishing levels of infection. A
reverse genetics system for NDV has been developed and used
to generate recombinant viruses stably expressing foreign an-
tigens (4, 22, 26, 27). Recombinant NDV (rNDV) grows to
high titers in embryonated chicken eggs and cell culture and
generates a strong immune response in murine and nonhuman
primate models, making this vector an attractive vaccine can-
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didate (4, 9, 22, 23). Finally, NDV codes for fewer proteins that
may compete for immunodominant epitopes between the viral
vector and the expressed foreign antigens.
Our group has previously generated an rNDV vector ex-
pressing a synthetic codon-optimized HIV-1 Gag protein and
demonstrated its ability to induce a potent Gag-specific CD8
T cell response in mice (5). In order to increase the immuno-
genicity of the rNDV vaccine, we sought to target the encoded
antigen to dendritic cells (DCs). DCs are the most efficient
antigen-presenting cells (APCs) described to date; however,
only a fraction of the antigen-pulsed DCs reach regional lymph
nodes, where cell-to-cell contact between DCs and T cells is
required for effective T cell induction (5, 8). To overcome this
limitation, antigens have been targeted to DCs by the conju-
gation/fusion of the antigen to DC receptor-specific monoclo-
nal antibodies (MAbs) or single-chain Fv (scFv) molecules (6).
Among the surface molecules expressed by dendritic cells,
DEC205 may be particularly suitable for DC targeting.
DEC205 is an endocytic receptor of the macrophage mannose
receptor family and is expressed on DCs in the T cell area of
lymphoid organs (15). More importantly, in addition to cross-
presenting antigens to CD8 T cells, DEC205 targets antigens
to the major histocompatibility complex (MHC) class II-posi-
tive late endosomal compartment, resulting in superior antigen
presentation compared with pinocytosis or phagocytosis (20).
In addition, DEC205 was shown previously to access the cross-
presentation pathway of many human HLA haplotypes (3). A
DNA vaccine encoding an HIV-1 Gag-scFv DEC205 fusion
protein increased both Gag antibody titers and the numbers of
Gag-specific gamma interferon (IFN-)-producing T cells
compared to a nontargeted vaccine in mice (25). In addition,
the Gag-specific immune response was further enhanced when
the targeted DNA vaccine was combined with synergistic Toll-
like receptor (TLR) ligands that induce interferon production
and consequently induce the maturation of DCs (16). In this
study, using a murine model, we confirm the efficacy of rNDV
as a vector for the expression and delivery of the HIV Gag
protein and demonstrate that the targeting of the Gag protein
to DCs through the DEC205 receptor enhances the anti-Gag
immune response.
MATERIALS AND METHODS
Cells, viruses, and animals. Vero, A549, CHOneo, CHOmDEC205, and CV-1
cells where maintained in Dulbecco modified Eagle medium containing 10%
fetal bovine serum (FBS) and 1% penicillin streptomycin. Wild-type New York
City Board of health vaccinia virus (Vac-Wt) was kindly provided by Gomez
Yafal at Therion Biologicals, and recombinant vaccinia virus expressing HIV-1
Gag (Vac-gag) (vP1287) was kindly provided by Matthias J. Schnell. Both vac-
cinia viruses were grown and titrated in CV-1 cells. Six- to eight-week old female
BALB/c mice and CxB6 F1 mice were obtained from Charles River. All animal
care and procedures were in accordance with the animal experimentation guide-
lines of the National Institutes of Health (NIH).
Generation of full-length rNDV-LaSota cDNA. To generate full-length rNDV-
LaSota cDNA, the LaSota genome was divided to 9 segments, and each segment
was obtained by reverse transcription (RT)-PCR using RNA purified from the
NDV-LaSota virus, followed by cloning into the pGEM-T vector (Promega) and
sequencing. Each segment was then digested, ligated, and inserted into the
HindIII and BssHII positions of vector pSL1180 (22). Finally, a segment which
contained the sequence of the hepatitis delta virus (HDV) ribozyme and T7
terminator was digested from an rNDV-Hitchner B1 cDNA plasmid (22) using
a BssHII enzyme and ligated into the BssHII position of the plasmid containing
full-length rNDV-LaSota cDNA. The primer sequences are available upon re-
quest.
Generation of rNDV vaccine vectors. scFv-Gagp41 open reading frame (ORF)
sequences were obtained by PCR using plasmids pE-mISO-olla-P41 and pE-
mDEC-olla-p41 as templates, which code for scCont-Gagp41 and scDEC-
Gagp41, respectively (25). The green fluorescent protein (GFP) ORF sequence
was obtained by PCR using pEGFP-C1 (BD Biosciences-Clontech) as a tem-
plate. The amplified cDNAs were cloned into NDV transcriptional units con-
taining NDV-specific gene start and gene end sequences. An optimal Kozak
translation sequence was also included just upstream of the ATG. In order to
follow the rule of six, necessary for NDV replication, nucleotides were inserted
after the stop codon when needed. The scFv-Gagp41 and GFP transcriptional
units were inserted into the SacII site in the NDV-LaSota genome between the
P and M genes. The obtained plasmids were used to rescue the recombinant
viruses by using previously described methods (22). The rescued viruses, rNDV-
L-scDEC-Gagp41, rNDV-L-scCont-Gagp41, and rNDV-L-GFP, were passaged
three times in eggs, and viral clones were isolated by limiting dilution in eggs.
Clones were used to generate vector stocks from which the inserted segments
were amplified using RT-PCR and sequenced. scFV-Gagp41-expressing rNDV
vectors were titrated by indirect immunofluorescence in Vero cells infected with
different dilutions of the vectors and by using an anti-NDV rabbit serum followed
by incubation with fluorescein isothiocyanate (FITC)-conjugated anti-rabbit im-
munoglobulin G (IgG) (Sigma-Aldrich). rNDV-L-GFP virus was titrated by
direct fluorescence on Vero cells.
rNDV growth kinetics in embryonated chicken eggs. Ten-day-old eggs were
infected with 100 fluorescence-forming unit (FFU) of each of the different rNDV
vectors. Allantoic fluids were harvested at 24, 48, 72, and 96 h after infection.
Viral titers were measured by indirect immunofluorescence on Vero cells for the
scFv-Gagp41-expressing vectors and by direct fluorescence for rNDV-L-GFP.
Transgene expression profile. Vero cells were inoculated with each rNDV
vector at a multiplicity of infection (MOI) of 1. Cell lysates and cell supernatant
were harvested 12, 24, and 36 h after infection. Proteins were separated by
SDS-PAGE and transferred onto a nitrocellulose membrane. Membranes were
then incubated with anti-NDV rabbit serum followed by incubation with anti-
rabbit IgG peroxidase-labeled antibody (Amersham) to detect NDV proteins.
For the detection of scFv-Gagp41, membranes were incubated with an anti-
HIV1 p24 monoclonal antibody (Abcam) followed by anti-mouse IgG peroxi-
dase-labeled antibody (Amersham).
DEC205 binding. Vero cells were infected with either rNDV-scDEC-Gagp41
or rNDV-scCont-Gagp41 at an MOI of 5. At 24 h postinfection, the supernatant
was harvested and cleared from cell debris by centrifugation at 10,000 rpm for 30
min. Supernatants were then incubated with either CHOneo or CHOmDEC205
cells for 30 min at 4°C. The cells were washed and incubated with an FITC-
labeled mouse anti-E. coli OmpF linker and mouse langerin fusion sequence
(anti-OLLAS) antibody for 30 min at 4°C, and cells were then washed and
analyzed by flow cytometry.
Immunizations of mice. Groups of 4- to 6-week-old female CxB6 F1 mice
where intranasally immunized with 5  105 FFU of rNDV-L-scDEC-Gagp41,
rNDV-L-scCont-Gagp41, or rNDV-L-GFP. Four weeks later mice were boosted
with 106 FFU of the same vector.
Challenge infections with Vac-gag and Vac-Wt. Four weeks after the boost,
groups of CxB6 F1 mice (5 mice per group) were challenged with 106 PFU of
either an HIV-1 Gag-expressing vaccinia virus (Vac-gag) or a wild-type vaccinia
virus (Vac-Wt). Six days after the challenge, mice were sacrificed, and their lungs
were extracted and homogenized for vaccinia virus titration on CV-1 cells. Two
days after the infection CV-1 cells were fixed and stained with 0.1% crystal violet
solution to count the number of vaccinia virus plaques.
Dose-response experiments. Groups of 6- to 8-week-old female BALB/c mice
(n  10) were intranasally immunized in a homologous prime-and-boost vaccine
regimen with graded doses (10-fold dilutions) of either rNDV-L-scDEC-Gagp41
or rNDV-L-scCont-Gagp41. The mice were allowed to rest for 3 weeks between
the prime and boost. The following groups were used: mice primed with 5  105
FFU and boosted with 106 FFU of NDV-L-scDEC-Gagp41 (DEC A group),
mice primed with 5  105 FFU and boosted with 106 FFU of NDV-L-scCont-p41
(Cont A group), mice primed with 5  104 FFU and boosted with 105 FFU of
NDV-L-scDEC-Gagp41 (DEC B group), mice primed with 5 104 FFU and
boosted with 105 FFU of NDV-L-scCont-p41 (Cont B group), mice primed with
5  103 FFU and boosted with 104 FFU of NDV-L-scDEC-Gagp41 (DEC D
group), and mice primed with 5  103 FFU and boosted with 104 FFU of
NDV-L-scCont-p41 (Cont D mice). Negative-control mice (GFP group) were
primed with 5  105 FFU of rNDV-L-GFP and boosted with 106 FFU of the
same vector. Three weeks after the last immunization, mice (n  5) were
challenged intranasally with 106 PFU of either Vac-gag or Vac-Wt. Five days
after the challenge, lungs were extracted and homogenized, and vaccinia virus
titers were determined by using a plaque assay on CV-1 cells.
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Serum antibody titers. For the detection of HIV Gagp41-specific antibodies,
high-protein-binding enzyme-linked immunosorbent assay (ELISA) plates were
coated overnight at 4°C with 0.2 g/ml of Gagp41 protein in phosphate-buffered
saline (PBS). Plates were washed three times with PBS-Tween 20 (0.02%) and
blocked for 2 h using PBS–1% bovine serum albumin (BSA) at room tempera-
ture. Plates were washed with PBS-Tween 20 and incubated with serial dilutions
of mouse sera for 3 h at 37°C. Plates were washed five times with PBS-Tween 20
(0.02%) and incubated with alkaline phosphatase-labeled anti-mouse IgG
(Southern Biotech) antibody for 3 h at 37°C. Plates were washed, and the optical
density (OD) was determined at 405 nm with a plate reader after the addition of
p-nitrophenyl phosphate solution (Sigma). For the detection of NDV-specific
antibody, the same protocol was followed, with the exception that medium-
protein binding plates were coated with sucrose cushion (30%)-purified rNDV-
LaSota at a concentration of 0.5 g/ml, and bound anti-NDV antibodies were
detected by alkaline phosphatase-labeled anti-mouse heavy-plus-light-chain
(HL) antibody (Southern Biotech).
Intracellular cytokine staining. Bulk splenocytes were restimulated with either
0.2 g/ml of an HIV Gagp41 pool mix of 15-mer peptides staggered every 4
amino acids along the HIV-1 Gagp41 sequence or 2 g/ml of a nonreactive
peptide (HIV Gag p17 pool 1) as a negative control (Proteomic Resource
Center, the Rockefeller University) in the presence of 2 g/ml of anti-CD28
antibody (eBioscience) for 6 h, adding brefeldin A (Sigma-Aldrich) the last 4 h.
After blocking Fc receptors (rat anti-mouse CD16/CD32; BD Biosciences),
cells were stained with the antibodies CD3-Pacific Blue, CD8-FITC, and CD4-
peridinin chlorophyll protein (PerCP) (eBioscience) for 20 min at 37°C. Dead
cells were excluded by using Aqua Live/Dead stain (Invitrogen). Cells were
washed, fixed (Cytofix/Cytoperm Plus; BD Biosciences), permeabilized with Perm-
Wash, and stained with antibodies to IFN- (Alexa Fluor 700), tumor necrosis
factor alpha (TNF-) (CY7-phycoerythrin [PE]), and interleukin-2 (IL-2) (allo-
phycocyanin) (eBioscience) for 15 min at room temperature. Stained samples
were analyzed by flow cytometry using a BD LSRII instrument, and Flowjo
software (Tree Star) was used for data analysis. Data are representative of three
experiments where spleens from two mice were pooled in each experiment. We
acquired 100,000 events in the live-cell/CD3 gate; the x axis indicates CD8/
CD4 cells, and the y axis indicates cytokine expression (IFN-, TNF-, and
IL-2). To examine multiple-cytokine-expressing T cells, we gated on either CD3
CD4 or CD3 CD8 T cells that are also positive for one cytokine and
examined the total number of cells that expressed either one or both of the other
two cytokines. The mean total number of cytokine-forming cells was calculated
as the difference between Gag-stimulated samples and samples stimulated with
the unreactive peptide.
Tetramer staining. Isolated splenocytes and lung cells were blocked with Fc
block (rat anti-mouse CD16/CD32; BD Bioscience) for 1 h at room temperature.
Cells were then washed with fluorescence-activated cell sorter (FACS) buffer
(2% BSA–PBS) and stained for 30 min using a PE-Gag tetramer (H-2Kd-
restricted AMQLMLKETI epitope; Beckman Coulter) and antibodies to CD3
(Pacific Blue), CD8 (FITC), and CD4 (PerCP) (eBioscience). Dead cells were
excluded by using Aqua Live/Dead stain (Invitrogen). Stained samples were
analyzed by flow cytometry using a BD LSRII instrument, and Flowjo software
(Tree Star) was used for data analysis.
Statistical analysis. An unpaired two-tailed t test was used to deduce the
difference between groups of vaccinated mice. A P value of 0.05 indicates
significance between two groups (indicated with an asterisk in the figures).
RESULTS
Characterization of the viral vaccine constructs. An rNDV
expressing the HIV Gag protein was previously generated, and
the optimal insertion site in the NDV genome to achieve the
highest level of Gag expression that consequently induced the
most potent Gag-specific cellular immune response was deter-
mined (5). Using previously defined reverse genetics tech-
niques, rNDV vectors expressing either a targeted or untar-
geted HIV Gagp41 protein were generated in the lentogenic
LaSota background (Fig. 1A). For the vector expressing
DEC205-targeted HIV Gagp41, rNDV-L-scDEC-Gagp41,
HIV Gagp41 conjugated to the variable regions of the light
and heavy chains of the parental anti-DEC205 antibody
(NLDC145) (25) was inserted between the P and M genes of
the rNDV genome. The Gagp41 gene expresses a truncated
version of the strain NL4-3 Gag protein. The inserted con-
struct presented a typical scFv structure. The variable domain
of the immunoglobulin heavy chain (VH) was linked to light
chain 1 via an interchain linker in a VH-VL orientation, and
scFv was fused in frame to the Gagp41 sequence. In addition,
a 14-amino-acid sequence corresponding to the OLLAS
epitope tag was inserted between scFv and the Gagp41 se-
quence. Similarly, for the untargeted vector, HIV Gagp41
fused to the variable regions of the light and heavy chains of a
nonreactive antibody (the same isotype as NLDC145) was in-
serted between the P and M genes of the NDV genome,
rNDV-L-scCont-Gagp41. The negative-control vector rNDV-
L-GFP consisted of an rNDV vector with a GFP gene inserted
between the P and M genes (Fig. 1A). Rescued viral clones
were isolated by limiting dilution in eggs, and the inserted
segments were amplified by reverse transcription-PCR and
sequenced in order to confirm the integrity of the vaccine
constructs.
In order to investigate whether the insertion of the foreign
antigens in the NDV genome might have differentially affected
the growth of one vector versus the other, we inoculated 10-
day-old eggs with 100 FFU of the different rNDV vectors. The
inoculated eggs were incubated at 37°C, and allantoic fluids
were harvested every 24 h. The presence of infectious virus was
determined by indirect immunofluorescence on Vero cells,
probing for the scFv-Gagp41-expressing vectors, and by direct
fluorescence for the GFP-expressing rNDV vector (Fig. 1B).
At each time point, we found similar virus titers in the har-
vested allantoic fluids, indicating that all three rNDV vectors
had similar replication and growth kinetics.
To determine the level of scFv-Gagp41 expression driven by
the rNDV vectors, Vero cells were infected at an MOI of 1
with rNDV-L-scDEC-Gagp41, rNDV-L-scCont-Gagp41, or
rNDV-L-GFP as a negative control. Cell lysates as well as
supernatants were harvested at 12, 24, and 36 h postinfection,
and a Western blot analysis was performed (Fig. 1C). At each
time point we observed similar NP levels, suggesting compa-
rable replication kinetics of the viral vectors in Vero cells. In
addition, cells infected with the scFv-Gagp41-expressing rNDV
vectors showed equivalent scFv-Gagp41 levels in the cell ly-
sates as well as in the supernatants.
In order to confirm that scDEC-Gagp41 expressed by cells
infected with rNDV-L-scDEC-Gagp41 retained DEC205 bind-
ing activity, Chinese hamster ovary cells stably expressing mu-
rine DEC205 (CHOmDEC205) or control CHO cells
(CHOneo) were incubated with the supernatant of Vero cells
infected with either rNDV-L-scDEC-Gagp41 or rNDV-L-
scCont-Gagp41. scFv-Gagp41 binding was detected by flow
cytometry analysis using an OLLAS-specific, FITC-labeled an-
tibody (Fig. 1D). Supernatants from rNDV-L-scDEC-Gagp41-
infected Vero cells showed binding activity toward CHOm-
DEC205 but not toward CHOneo cells; these supernatants
retained binding activity even when diluted 1/50 in PBS. As
expected, supernatants from cells infected with rNDV-L-sc-
Cont-GagP41 showed binding to neither CHOmDEC205 nor
CHOneo cells. In summary, both the rNDV-L-scDEC-Gagp41
and rNDV-L-scCont-Gagp41 vectors had similar growth kinet-
ics and equivalent transgene expression profiles; however, only
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supernatants from rNDV-L-scDEC-Gagp41-infected cells
demonstrated DEC205 binding activity.
rNDV expressing a DEC205-targeted HIV-1 Gag antigen
improves Gag-specific but not vector-specific antibody re-
sponses. DEC205-targeted antigens were previously shown to
enhance antigen-specific antibody responses when encoded by
a plasmid DNA vaccine (25). To examine the antibody profile
induced by rNDV vaccination, groups of six CxB6 F1 mice were
immunized with 5  105 FFU of rNDV-L-scDEC-Gagp41,
rNDV-L-scCont-Gagp41, or rNDV-L-GFP. Four weeks later
mice were boosted with 106 FFU of the same vaccine vector.
rNDV-specific antibodies were quantified by using an ELISA
for the detection of total antibody against sucrose cushion-
purified rNDV-LaSota (Fig. 2A and B). There were no signif-
icant differences in NDV-specific antibody titers in any of the
3 groups of vaccinated mice either at 30 days postprime (Fig.
2A) or at 30 days postboost (Fig. 2B). As expected, boosting
with the rNDV vaccine vectors increased vector-specific anti-
body responses within each group (Fig. 2A and B). Next, an
ELISA was performed to detect total serum IgG specific for
the Gagp41 protein. Gag-specific total IgG antibodies were
below our detection limit 30 days postprime (data not shown);
however, 30 days after the boost, serum from mice vaccinated
with rNDV-L-scDEC-Gagp41 showed a significant increase in
levels of Gag-specific IgG compared to that in serum obtained
from mice immunized with the nontargeted vector (Fig. 2C).
These data indicate that even though vector-specific antibody
responses were similar for all 3 groups of vaccinated mice
(implying comparable replication kinetics in mice), the rNDV
expressing a DEC205-targeted HIV Gagp41 antigen did en-
hance the antigen-specific humoral immune response com-
pared to an rNDV expressing a nontargeted antigen.
Induction of HIV Gagp41-specific cellular immune re-
sponses. The hallmark of replication-competent viral vaccine
vectors is the induction of potent antigen-specific cellular im-
mune responses (31). To evaluate T cell immunity generated
by an rNDV expressing a DEC205-targeted antigen, we mea-
sured HIV Gag-specific T cell responses induced by rNDV-L-
scDEC-Gagp41 immunization and compared them to re-
sponses induced by rNDV-scCont-Gagp41 and rNDV-L-GFP.
FIG. 1. Characterization of the viral vaccine constructs. (A) Schematic diagram of the different recombinant NDVs expressing either the
DC-targeted or the untargeted HIV Gag protein. A transcriptional unit containing either scDEC-Gagp41, scCont-Gagp41, or GFP was
inserted between the P and M genes of NDV. (B) Growth kinetics of NDVs in embryonated chicken eggs. (C) Cell lysates and supernatants
from Vero cells infected for 12, 24, or 36 h with rNDV-L-scDECGagp41, rNDV-scCont-Gagp41, or rNDV-L-GFP viruses (MOI of 1) were
subjected to SDS-PAGE and were transferred onto nitrocellulose membranes. Membranes were immunoblotted by using anti-Gag p24
antibody, anti-NDV rabbit serum, or anti-actin as a loading control. (D) Binding to the murine DEC205 receptor. Binding to CHOmDEC205
or CHOneo control cells of supernatants from Vero cells infected for 36 h with recombinant NDV-L-scDEC-Gagp41 or NDV-L-scCont-
Gagp41 at an MOI of 5. Supernatants from NDV-L-scDEC-Gagp41-infected cells were either undiluted or diluted 1/2, 1/10, 1/20, or 1/50
in PBS. scFV-Gagp41 fusion proteins were detected by an OLLA-specific, FITC-labeled antibody.
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FIG. 2. Serum antibody titer after vaccination. (A and B) Total anti-NDV serum antibody titer in CxB6 F1 mice (6 mice per group) was













FIG. 3. Vaccine-induced HIV Gag-specific immune response. (A) Bulk splenocytes were assessed for T cell immunity 1 week after prime and
1 week after boost. Splenocytes were restimulated for 6 h either with unreactive peptides (p17 pool 1) or with an HIV Gagp41 peptide mix, and
IFN-, TNF-, and IL-2 production was evaluated by intracellular cytokine staining in CD3 CD4 T cells and CD3 CD8 T cells. Arrows
indicate CD8 T cells. (B and C) Cytokine profile of CD3 CD4 T cell (B) and CD3 CD8 T cell (C) responses in vaccinated mice 1 week
after prime and 1 week after boost. G, IFN--expressing cells; T, TNF--expressing cells; L, IL-2-expressing cells. (D) Accumulation of
Gag-specific CD8 T cells in the spleen (left) and in the lungs (right) 1 week after prime and 1 week after boost. HIV Gag-specific T cell responses
in the spleen and lungs of vaccinated CxB6 F1 mice were examined by using HIV Gag tetramer staining of total CD8
 CD3 cells. Data are
representative of 3 different experiments; data for 2 mice were pooled in each experiment.
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Groups of six CxB6 F1 mice were immunized in a homologous
prime-boost vaccine regimen employing each of the above-
mentioned vaccine vectors. At two time points, 7 days after the
prime and 7 days after the boost, lungs and spleens were
harvested. Splenocytes were subsequently used in a multipara-
metric intracellular cytokine assay that measured T cell cyto-
kine responses against a library of 15-mer peptides represent-
ing the whole HIV-1 Gagp41 sequence; a mix of nonreactive
peptides (P17 pool) was included as a negative control (Fig.
3A). As expected, mice vaccinated with rNDV-L-GFP showed
only background levels of cytokine-expressing T cells. Seven
days after the first immunization, mice vaccinated with the
scFv-Gagp41-expressing vectors demonstrated similar levels of
cytokine-producing T cells (Fig. 3A to C). However, 7 days
after the boost, the numbers of Gag-specific CD4 T cells and
CD8 T cells producing IFN-, TNF-, and IL-2 were higher
in the mice that received the DEC205-targeted vaccine than in
the mice that received the nontargeted vaccine (Fig. 3A to C).
rNDV-L-scDEC-Gagp41 vaccination induced a 2-fold in-
crease of the amount of cytokine-producing CD8 T cells
compared to the nontargeted control vaccine (Fig. 3A and
C, compare dark gray and dark blue bars). Splenocytes
pulsed with the control peptide mix showed only back-
ground levels of cytokine production (Fig. 3A). Since T cells
producing multiple cytokines are closely associated with
protective immunity (17), we examined the capacity of the
vaccine-induced T cells to secrete multiple cytokines such as
IFN-, IL-2, and TNF- (Fig. 3B and C). DEC205-targeted
vaccination induced more polyfunctional CD4 and CD8
T cells that produced 2 or more cytokines than did the
nontargeted vaccine. Triple-cytokine-producing CD4 and
CD8 T cells (IFN- positive [IFN-], IL-2, and TNF-
) were predominant in mice vaccinated with the DEC205-
targeted vaccine 7 days after the boost (Fig. 3B and C). In
addition, rNDV-L-scDEC-Gagp41 vaccination induced
more CD4 T cells that coexpressed TNF- and IL-2 (Fig.
3B) and more CD8 T cells that expressed both IFN- and
TNF- than the rNDV-scCont-Gagp41 vaccine 7 days after
the boost (Fig. 3B and C). These data indicate that targeting
the rNDV-expressed antigen to dendritic cells improves the
induction of a potent and a broad antigen-specific T cell-
mediated immune response. To examine the accumulation
of vaccine-induced Gag-specific CD8 T cells, we stained
single-cell suspensions prepared from the lungs and the
spleens of vaccinated mice with an MHC class I Gag tet-
ramer (H-2Kd-restricted epitope). Mice vaccinated with
rNDV expressing the DEC205-targeted Gagp41 antigen
showed considerably more CD3 CD8 Gag tetramer-pos-
itive lymphocytes in the spleen and in the lungs 7 days after
the boost (Fig. 3D). Mice vaccinated with rNDV-L-GFP
showed low background levels of tetramer-positive cells
(Fig. 3D). The Gag tetramer staining results were consistent
with the cytokine expression analysis where we observed
minimal differences in the ability scFv-Gagp41-expressing
vectors to induce antigen-specific T cells at 7 days after the
prime, whereas the DEC205-targeted vector performed con-
siderably better than did the nontargeted vector after the
boost. These data demonstrate that the DC-targeted vaccine
FIG. 4. Challenge with Vac-gag in mice immunized with the NDV-L-scFv-Gagp41 viruses. Groups of 10 female CxB6 F1 mice were immunized
intranasally with 105 FFU of either NDV-L-scDEC-Gagp41 or NDV-L-scCont-Gagp41. Negative-control mice were inoculated with NDV-L-GFP.
Four weeks later, animals were boosted with 106 FFU of the same virus. Four weeks after the boost, five mice per group were challenged with 106
PFU of Vac-Wt or Vac-gag. (A) Six days after the infection with vaccinia viruses, mice were sacrificed, lungs were homogenized in 1 ml of PBS,
and vaccinia virus titers in CV-1 cells were determined. (B and C) Weight loss was monitored daily for 6 days after the Vac-gag (B) and Vac-Wt
(C) challenges.
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enhanced both the quantity and the quality of the antigen-
specific cellular immune response.
Protection from viral challenge. Next, we wanted to eval-
uate whether the vaccine-induced enhancement of the Gag-
specific immune response correlated with better protective
immunity. Since HIV-1 cannot infect mice, the ability of the
different rNDV vectors to elicit a Gag-specific protective
immune response at mucosal sites can be tested by infecting
the vaccinated mice with a vaccinia virus expressing the HIV
Gag protein (Vac-gag). A more effective vaccine should
better control Vac-gag replication. Therefore, we chal-
lenged the previously vaccinated groups of CxB6 F1 mice
(n  5) with 106 PFU of either Vac-gag or wild-type vaccinia
virus (Vac-Wt) as a background control via the intranasal
route 4 weeks after the last immunization (Fig. 4). Four out
of five mice vaccinated with rNDV-L-scDEC-Gagp41 were
able to clear Vac-gag infection 6 days after challenge (Fig.
4A). Mice vaccinated with rNDV-L-scCont-Gagp41 were
not able to clear the Vac-gag infection but demonstrated
lower vaccinia virus lung titer loads than did rNDV-L-GFP-
vaccinated mice or mice challenged with Vac-Wt (Fig. 4A).
In addition, mice vaccinated with the DEC205-targeted vac-
cine stopped losing weight 3 days after Vac-gag challenge
and were able to regain their initial weight by day 6 after the
viral challenge, whereas mice that received the control vac-
cine rNDV-L-scCont-Gagp41 did not start to regain weight
before the fifth day after Vac-gag challenge (Fig. 4B). As
expected, all groups of mice challenged with Vac-Wt showed
no protection against the viral challenge, indicating that the
immune responses generated by vaccination were Gag spe-
cific (Fig. 4C). These data demonstrate that an rNDV ex-
pressing a DEC205-targeted antigen significantly enhanced
antigen-specific cell-mediated immune responses compared
to an rNDV expressing a nontargeted antigen, and impor-
tantly, this enhancement correlated with a superior ability to
control viral infection.
Dose-response efficacy of the DEC205-targeted vaccine ver-
sus the control. In order to better quantify the improvement
conferred by the DEC205-targeted antigen in the context of
an rNDV vaccine vector, we vaccinated groups of 6- to
8-week-old female BALB/c mice with graded doses (10-fold
dilutions) of rNDV-L-scDEC-Gagp41 (DEC group) or
rNDV-L-scCont-Gagp41 (Cont group). Negative-control
mice (GFP group) received the highest dose of rNDV-L-
GFP (Fig. 5A). The rNDV-specific serum antibody titer was
tested for all groups of mice to ensure the adequate inocu-
lation of the vaccine vectors (data not shown). Three weeks
after the boost, mice were challenged with either Vac-gag or
Vac-Wt as a background control. As expected, the DEC A
group was the most efficient in controlling Vac-gag infec-
tion, followed closely by the DEC B and Cont A groups (Fig.
5B to D), which showed a similar ability to control the
Vac-gag infection. In addition, the DEC C group showed
equivalent Vac-gag lung titers compared to the Cont B
group (Fig. 5B). Weight loss postchallenge correlated
closely with the ability of vaccinated mice to control the viral
challenge. Significant vaccine-induced protection was lost
for the groups of mice that received the lowest doses of the
vaccine vectors (DEC D, Cont C, and Cont D groups) and
the GFP negative control (Fig. 5B and D). All groups
showed no protective effect when challenged with Vac-Wt
virus, confirming the specificity of the immune response
(Fig. 5C and D). These data indicate that the protective
immune response induced by vaccination with rNDV-L-
scDEC-Gagp41 is equivalent to the response generated by
vaccination with a 10-times-more-concentrated dose of the
control nontargeted vector rNDV-L-scCont-Gagp41. The
DEC205-targeted vaccine is 10-fold better than the control
vector in controlling vaccinia virus Gag infection.
DISCUSSION
Live viral vaccine vectors have historically provided the
most effective protection against viral infection and disease
(31). These vaccines were paramount in the eradication
efforts for devastating diseases like smallpox, poliomyelitis,
yellow fever, and measles. Following the concept of a “Jen-
nerian” immunization, a live attenuated viral vaccine elic-
ited cross-protective immunity against a heterologous but
closely related virus. Unfortunately, for safety reasons Jen-
nerian immunization cannot be applied for the generation
of HIV vaccines (18). Consequently, viral vectors such as
adenovirus, canarypox virus, and others have been engi-
neered to express HIV antigens and therefore elicit immune
responses against one or more HIV proteins (31). These
vectors were shown to be safe enough to be tested in human
clinical trials; however, their effectiveness in eliciting a pro-
tective immune response remains in doubt. A live replicat-
ing viral vaccine vector has the ability to trigger innate and
adaptive immune responses that usually become activated
during the course of a natural infection. The problem lies in
that the immune responses are typically directed against the
vector’s own protein and not the encoded HIV antigen,
resulting in a somewhat weak HIV vaccine vector. There-
fore, to achieve an effective HIV vaccine, it is essential to
improve the transgene-specific immune response in the con-
text of a live viral vaccine vector.
Previous studies have demonstrated that the targeting of
an antigen to DCs through the DEC205 endocytic receptor
by way of conjugating the antigen to an anti-DEC205 anti-
body increases the efficiency of antigen presentation on
MHC class I and II molecules and enhances the magnitude,
the breadth, and the quality of the antigen-specific immune
response (3, 20, 25). In all of those studies, the addition of
DC maturation signals, like TLR agonists, improved cell-
mediated immunity due to the induction of high levels of
type I interferon. For this reason, we sought to exploit the
ability of NDV to induce a potent type I interferon response
(22, 23). We therefore generated an rNDV vector express-
ing a secreted HIV Gagp41 protein that is targeted to DCs
through coupling to a single-chain antibody (scFv) directed
against DEC205. We compared the ability of the targeted
vaccine to induce a potent Gag-specific immune response to
that of an rNDV that expresses a nontargeted HIV Gagp41
protein. We have previously demonstrated that in the con-
text of an rNDV vector, the potency of the antigen-specific
immune response correlates with the expression level of the
antigen itself (5). In order to exclude that possibility, we
confirmed that both vectors have equivalent replication ki-
netics and transgene expression profiles. In addition, only
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the DC-targeted antigen showed binding to CHO cells ex-
pressing the murine DEC205 receptor. Next, we immunized
mice with a homologous prime-and-boost vaccination regi-
men and demonstrated that even though the vector-specific
humoral immune responses were equivalent in all groups of
mice, we observed higher HIV Gag-specific IgG antibody
titers in the serum of mice that received the DEC205-tar-
geted vaccine.
The principal purpose of the rNDV vaccine vector is to
elicit a strong antigen-specific T cell-mediated immune re-
sponse. In order to examine whether DEC205 targeting of
the HIV-1 Gag antigen would lead to enhanced cellular
immunity in the context of an rNDV vector, we examined
the accumulation of Gag-specific CD3 CD8 T lympho-
cytes in the lungs and in the spleen of vaccinated mice using
Gag tetramer staining. In both the spleen and the lungs, we
observed an increase in numbers of HIV Gag-specific CD8
T cells in mice vaccinated with the DEC205-targeted vaccine
compared to those in mice vaccinated with the nontargeted
vaccine.
We subsequently analyzed the Gag-specific cytokine se-
cretion profile generated by CD4 T cells and CD8 T cells
in vaccinated mice. The DEC205-targeted vaccine induced
more T cells that expressed IFN-, IL-2, and TNF- than
did the nontargeted vaccine. In addition, the DEC205-tar-
geted vaccine produced more polyfunctional T cells that
expressed 2 or more cytokines. Our results indicate that the
enhancement of the cellular immune response was readily
measurable after the vaccine boost. We did observe a trend
where the DEC205-targeted vaccine improved vaccination
efficiency after the first immunization; however, the levels of
antigen-specific responses at that time point were low and
not readily quantifiable. This observation is consistent with
data from previous studies that indicated a requirement for
a boost in the context of viral vaccine vectors (5, 23). Over-
all, the targeting of the HIV-1 Gag antigen to DCs in the
context of an rNDV vector improved the quantity and the
quality of the Gag-specific immune response.
Finally, in order to correlate the enhancement of the T
cell-mediated immune response with protective immunity,
we challenged the vaccinated groups of mice with a live
vaccinia virus expressing the HIV-1 Gag protein. Mice vac-
cinated with the DEC205-targeted vaccine performed better
in controlling the Vac-gag infection. In addition, dose-
response experiments demonstrated that the targeting of the
rNDV-encoded antigen to the DEC205 receptor on den-
dritic cells increased the efficiency of vaccination by 10-fold.
Nchinda et al. (25) previously observed that a DNA vaccine
expressing a DEC205-targeted antigen provided better pro-
tective immunity at low doses but not at high doses of DNA
than did a DNA vaccine expressing a nontargeted antigen
(25). In that study, dose-response experiments did not dem-
onstrate a saturating effect when high doses of the rNDV
vaccine were administered. This dichotomy can be attrib-
uted to the probability that we did not reach saturating
doses in our experiments. However, this could also be ex-
plained by the superior ability of live viral vaccine vectors to
recruit and activate dendritic cells compared to DNA vac-
cine vectors.
HIV-specific T lymphocytes play an essential role in the
immune control of viral replication. The depletion of CD8
T cells in simian immunodeficiency virus (SIV)-infected
monkeys abrogated the control of viral replication (33);
CD8 lymphocytes have been shown to exert an immune
pressure on HIV replication, inducing the virus to mutate
within epitopes (29); and different genetic studies demon-
strated a clear association between some HLA class I alleles
and the control of HIV replication in humans (10, 13). In
this study we describe a strategy to improve the vaccination-
induced HIV-specific cell-mediated immune response using
rNDV as a delivery vector. T cell-based vaccines are unlikely
to induce sterilizing immunity against HIV but may control
replication after infection (7). A potent immune response in
a conserved region of an HIV protein may force escape
mutants with a reduced viral replication capacity (21). HIV
Gag is highly conserved among sequenced isolates. Previous
studies provided evidence for a possible role of Gag-specific
CD8 T cells in the control of chronic HIV infection (12, 14,
19). Therefore, we chose HIV Gag as our model antigen.
However, this strategy could be applied to any other HIV
proteins, such as Nef, Pol, and Env, especially since NDV
was shown previously to accommodate the whole Gagp55
gene but also larger genes such as the severe acute respira-
tory syndrome coronavirus (SARS-CoV) spike (S) glyco-
protein gene (5, 9).
The immunological correlates for an effective HIV-1 vac-
cine are unknown; nevertheless, it is widely believed that
protective vaccine-induced immune responses need to be
more potent and durable in both systemic and mucosal
compartments (2). To that end, a ’heterologous prime-
boost” vaccine regimen, consisting of a DC-targeted protein
prime followed by a plasmid DNA boost, induced a more
potent immune response than did a homologous prime-
boost DNA vaccination (24). Each vaccine vector induced a
different type of immune response (CD4 T cells versus
CD8 T cells). This complementary vaccination regimen
translated into a faster accumulation of antigen-specific
CD8 T cells to mucosal sites after challenge (24).There-
fore, it will be interesting to test whether a heterologous
vaccine regimen consisting of a DEC205-targeted antigen
FIG. 5. Dose-response efficacy of the DEC205-targeted vaccine versus the control. (A) Immunization regimen. Groups of female BALB/c mice
were immunized with graded doses of NDV-L-scDEC-Gagp41 or NDV-L-scCont-Gagp41. Negative-control mice were immunized with NDV-L-
GFP. For the DEC A group, mice were primed with 5  105 FFU and boosted with 106 FFU of NDV-L-scDEC-Gagp41; for the Cont A group,
mice were primed with 5  105 FFU and boosted with 106 FFU of NDV-L-scCont-Gagp41. The vaccination dose from group A (DEC and Cont)
was serially diluted (10-fold) and administered to groups B, C, and D. Three weeks after the boost, mice were challenged with 106 PFU of either
Vac-gag virus or wild-type vaccinia virus. Weight loss was monitored for 5 days postchallenge. (B) Weight loss following Vac-gag challenge.
(C) Weight loss following Vac-Wt challenge. (D) Vaccinia virus lung titers 5 days postchallenge. Five days after challenge, lungs were harvested,
and vaccinia virus titers in the lungs were determined by a plaque assay on CV-1 cells.
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encoded by different vectors, such as rNDV or DNA, as well
as a DC-targeted protein vaccine can elicit high-frequency,
polyfunctional CD8 T cells that efficiently traffic to both
systemic and mucosal compartments.
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